HiFiBiO Therapeutics’ Post

🔬 Exciting News in Oncology Research! 🌟 Merck and Moderna have embarked on a groundbreaking journey with the initiation of the INTerpath-002 Phase 3 trial. This pivotal study explores the potential of V940 (mRNA-4157) in combination with KEYTRUDA (pembrolizumab) for the adjuvant treatment of specific types of resected non-small cell lung cancer. #InnovationInHealthcare #ClinicalTrials #OncologyResearch

#HighlyCitedPapers 🔬 Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies, by Sneha et al. The purpose of this #review was to provide an update on how the presence of #cytochrome P450 impacts on standard of care drugs used to treat breast #cancer as well as discuss opportunities to exploit CYP expression for therapeutic intervention. 👀 https://lnkd.in/eitt5g65 #breastcancer #breast_cancer

📜 Read about the latest advancements in immuno-oncology in our whitepaper. ·        Dive into the science behind immuno-oncology ·        Learn about cutting-edge therapies and their potential ·        Explore the challenges we must overcome 👇 Click the link below to access the whitepaper! https://lnkd.in/gwvHsR4e #Cancer #Immunotherapy #Biotherapeutics #NBE #LargeMolecules #ImmunoOncology  #TherapiesAndChallenges #MedicalAdvancements 

🎥 Latest From SGO & ESGO: DUO-E Trial Highlights 🔍 Join Prof Jean-Francois Baurain as he presents critical data from the DUO-E trial at SGO and ESGO, exploring first-line treatment options for endometrial cancer. Learn about the impact of checkpoint inhibitors and the potential enhancements from combining durvalumab with chemotherapy and olaparib. Discover these updates.👇 For all ESGO & SGO 2024 videos, find the link in the comments! #MediMix #ESGO2024 #SGO2024 #EndometrialCancer #CancerResearch

Great visual on the challenges and benefits of well-engineered antibody-drug conjugates

Discuss strategies to manage and mitigate adverse events associated with bispecific antibodies in R/R MM. Join us on October 26 at 8:00 PM ET for an informative discussion. https://lnkd.in/eHhfU6Bq #mmsm #cancer #oncology

In this article featured in Nature Journal, Vlad Bogin, MD, FACP, CEO of Cromos Pharma, offers insights into the prevailing challenges of conducting cancer research in Ukraine. Please read the article: https://lnkd.in/dCFB-d8r #cro #clinicaltrials #ukraine #cancer #clinicalresearch

In our Phase 2 VIRO-15 study, exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines. What does this mean? Olvi-Vec is giving hope to those patients with no available treatment, regardless of previous lines of therapy. #GNLX #Stage4needsmore #cancerresearch #drugdevelopment #cancer #nasdaq

𝗥𝗲𝗺𝗶𝗻𝗱𝗲𝗿: There are less than two months left to submit your full proposal for the 2024 RARE Grant—a #RUNX1 research opportunity co-funded by RRP & Alex's Lemonade Stand Foundation. The RARE Grant is a two-year award designed to fund research that will lead to the development of therapies for patients with RUNX1-FPD that will either intercept the transition from a precancer state (clonal hematopoiesis) to #MDS/#AML or prevent #cancer (before clonal hematopoiesis). Please take a moment to review the guidelines provided here: https://ow.ly/1Axo50PXWIH.

Unravelling the Mysteries of Colorectal Cancer Screening: Understanding the Important Reasons, Who to Identify, and How to Find Out in Laboratory Screening and Prevention. #oncowin #oncowincancercenter #CancerCareHospital #cancer #cancerawareness #cancercommunity #cancersupport #cancerpatient #Colorectalcancer #Oncologist #cancersurvivor #cancerresearch #cancertreatment